Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 16/20 | 0.57 |
| ▸ | CCNA2 | P20248 | 14/20 | 0.57 |
| ▸ | CDK2 | P24941 | 14/20 | 0.57 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.57 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL584764 | 0.93 | CHEK1 (0.53) | CHEK1CCNA2CDK2CCNA1TRPV3 | |
| SCHEMBL584609 | 0.86 | TRPV3 (0.42) | CHEK1CCNA2CDK2CCNA1TRPV3 | |
| SCHEMBL584081 | 0.86 | PDE10A (0.43) | CHEK1CCNA2CDK2CCNA1TRPV3 | |
| SCHEMBL583997 | 0.85 | CHEK1 (0.55) | CHEK1CCNA2CDK2CCNA1TRPV3 | |
| SCHEMBL594485 | 0.78 | CHEK1 (0.37) | CHEK1CCNA2CDK2CCNA1TRPV3 | |
| SCHEMBL584914 | 0.78 | PDE10A (0.46) | CHEK1CCNA2CDK2CCNA1TRPV3 | |
| SCHEMBL7846641 | 0.77 | CHEK1 (0.68) | CHEK1CCNA2CDK2CCNA1PDE10A | |
| SCHEMBL16784468 | 0.73 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL30757838 | 0.73 | CHEK1 (1.00) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL594923 | 0.72 | CHEK1 (0.60) | CHEK1CCNA2CDK2CCNA1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8591943-B2 | Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-11-26 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| EP-2417138-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | Schering Corporation (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | CHEK1 461/4885CCNA2 2476/4885CDK2 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.